Use of Probiotics in Preterm Infants - American Academy of ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
CLINICAL REPORT Guidance for the Clinician in Rendering Pediatric Care Use of Probiotics in Preterm Infants Brenda Poindexter, MD, MS, FAAP, COMMITTEE ON FETUS AND NEWBORN Probiotic products in the United States are available for use in the general abstract category of dietary supplements, bypassing the rigor of the US Food and Drug Children’s Healthcare of Atlanta and School of Medicine, Emory Administration (FDA) approval process in safety, efficacy, and manufacturing University, Atlanta, Georgia standards. As a result, currently available probiotics lack FDA-approved drug Clinical reports from the American Academy of Pediatrics benefit from labeling and cannot be marketed to treat or prevent disease in preterm expertise and resources of liaisons and internal (AAP) and external reviewers. However, clinical reports from the American Academy of infants, including necrotizing enterocolitis and late-onset sepsis. Despite lack Pediatrics may not reflect the views of the liaisons or the of availability of a pharmaceutical-grade product, the number of preterm organizations or government agencies that they represent. infants receiving probiotics in the United States and Canada is steadily Dr Poindexter was responsible for conceptualizing, writing, and revising the manuscript and considering input from all reviewers and increasing. According to recent reports from large collaborative databases in the board of directors; the author approved of the final manuscript as the United States, approximately 10% of extremely low gestational age submitted. neonates receive a probiotic preparation during their stay in the NICU, with The guidance in this clinical report does not indicate an exclusive course of treatment or serve as a standard of medical care. wide variation in practice among units. In sum, more than 10 000 preterm Variations, taking into account individual circumstances, may be infants have been enrolled in randomized clinical trials of probiotic appropriate. supplementation worldwide. Methodologic differences among study protocols All clinical reports from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, included different strains and combinations of therapy, masking of trials, and revised, or retired at or before that time. a priori definitions of the primary outcome measure. Large meta-analyses of The findings and conclusions in this article are those of the authors these trials have demonstrated the efficacy of multiple-strain probiotics in and do not necessarily represent the official position of the Centers for Disease Control and Prevention. reducing necrotizing enterocolitis and all-cause mortality, whereas the efficacy of single-strain probiotic preparations is less certain. In the absence of an This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed appropriate medical-grade product in the United States, dietary conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process supplement–grade probiotics, some of which have been the subject of recent approved by the Board of Directors. The American Academy of recalls for contamination, are being prescribed. Given the lack of FDA- Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication. regulated pharmaceutical-grade products in the United States, conflicting data DOI: https://doi.org/10.1542/peds.2021-051485 on safety and efficacy, and potential for harm in a highly vulnerable population, current evidence does not support the routine, universal Address correspondence to Brenda Poindexter, MD. E-mail: brenda.poindexter@emory.edu administration of probiotics to preterm infants, particularly those with a birth weight of ,1000 g. PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). Copyright © 2021 by the American Academy of Pediatrics FINANCIAL DISCLOSURE: The author has indicated she has no financial relationships relevant to this article to disclose. INTRODUCTION FUNDING: No external funding. There is a rapidly growing body of literature related to the developing intestinal microbiome and the use of probiotics and prebiotics in the To cite: Poindexter B, AAP COMMITTEE ON FETUS AND NEWBORN. Use of Probiotics in Preterm Infants. Pediatrics. maintenance of health and in the prevention and treatment of a number of 2021;147(6):e2021051485 disease states. In preterm infants, probiotics have been evaluated in Downloaded from www.aappublications.org/news by guest on May 27, 2021 PEDIATRICS Volume 147, number 6, June 2021:e2021051485 FROM THE AMERICAN ACADEMY OF PEDIATRICS
a number of randomized clinical trials In addition, a number of factors are required to meet higher regulatory for the prevention of severe known to alter the microbiota in standards. Indeed, the International necrotizing enterocolitis (NEC), late- preterm infants, including mode of Scientific Association for Probiotics onset sepsis, and all-cause mortality.1 delivery, exposure to antibiotics, use and Prebiotics expert panel noted Despite significant differences in the of histamine antagonists, and diet distinctive criteria for a “probiotic combination of probiotic preparations (especially human milk, promoting drug” with a specific indication for used in these trials and the lack of prevalence of Bifidobacterium treatment or prevention of disease to availability of a pharmaceutical-grade species).3,4 Numerous studies have require a defined strain(s) of live probiotic product in the United States, described intestinal dysbiosis microbe, proof of delivery of viable the number of preterm infants preceding the onset of NEC in probiotic at efficacious dose at end of receiving probiotics is steadily preterm infants, most commonly shelf-life, and a risk/benefit increasing. According to recent characterized by increased assessment to justify use based on reports from large collaborative Proteobacteria and decreased relative appropriate trials to meet regulatory databases in the United States, abundancies of Firmicutes and standards for drugs.8 It is important approximately 10% of extremely low Bacteroidetes species.5 Proposed to note that none of the probiotic gestational age neonates receive benefits of probiotics include trials published to date in preterm some type of probiotic during their preventing intestinal dysbiosis and infants for the prevention of NEC stay in the NICU, with wide variation assisting in metabolism of dietary meet these criteria or level of in practice among units.2 Although nutrients, leading to byproducts evidence. In the United States, some infant formulas for term infants essential for intestinal health. For probiotic products are typically available in the United States now example, Bifidobacterium longum manufactured as a dietary contain probiotics, formulas for subspecies infantis consumes human supplement. If a probiotic is going to preterm infants do not. milk oligosaccharides, promoting be marketed as a drug for treatment The purpose of this clinical report is a healthy intestinal microbiota.6 of a disease or disorder, it has to meet to (1) highlight differences among stricter requirements, including proof commercially available probiotic of safety and efficacy for its intended PROBIOTIC PREPARATIONS use through clinical trials and preparations and the current (lack of) regulatory standards in the United An expert panel convened by the approval by the US Food and Drug States; (2) outline potential risks International Scientific Association Administration before it can be associated with the use of probiotics, for Probiotics and Prebiotics defined sold.9,10 supporting a cautionary approach probiotics as “live microorganisms Probiotic preparations may include with their routine use in preterm that, when administered in adequate a single bacterial strain or infants; (3) review the current amounts, confer a health benefit to a combination of multiple strains. In evidence evaluating the use of the host.”7 In contrast, a prebiotic is addition to the particular bacterial probiotics in both prevention and a nutrient (oligosaccharides, for species on the probiotic product label, treatment of NEC, late-onset sepsis, example) that can modify the gut the preparations are highly variable and mortality; and (4) highlight the microbiota. Importantly, this in terms of the number of viable need for pharmaceutical-grade consensus panel proposed microorganisms both at the time of probiotics that have been rigorously benchmark standards, recognizing manufacturing and after shelf storage. evaluated for safety and efficacy. differences in regulatory approaches for probiotics in different countries. Studies evaluating the efficacy of oral Such differences have significant probiotics for the prevention of NEC INTESTINAL MICROBIOME OF THE implications for interpretation of have included single bacterial strains PRETERM INFANT studies of probiotic supplementation and mixtures of probiotics, often Over the past decade, the role of the and for recommendations for clinical including Lactobacillus, intestinal microbiome as a marker of use of probiotics in the NICU, Bifidobacterium, and/or health and disease in preterm infants including but not limited to the Saccharomyces species. Despite the has been increasingly recognized. number of colony-forming units observation that infants receiving Differences in the intestinal (CFUs) in the product, claims of human milk are colonized with microbiota among infants born at benefit that are not strain specific, Bifidobacterium breve and term and those born preterm have and the intent to support a healthy Bifidobacterium infantis,6 not all been demonstrated, with fewer gut microbiota versus to prevent probiotic preparations contain these bacterial species, less diversity, and disease. Unlike products used as bacteria. It is also important to note increased proportions of potentially dietary supplements, probiotics that the duration of colonization of pathogenic strains in preterm infants. labeled with the intent to treat are the gastrointestinal tract after Downloaded from www.aappublications.org/news by guest on May 27, 2021 2 FROM THE AMERICAN ACADEMY OF PEDIATRICS
administration of products containing and Penicillium species. Three of the earliest randomized trials Bifidobacterium organisms is Gastrointestinal mucormycosis has of probiotics in preterm infants discontinued may only persist for been reported in a preterm infant suggesting benefit were conducted a few months.11 In a recent study, 16 receiving contaminated ABC Dophilus outside the United States. Bin-Nun different commercially available Powder.17 et al23 (Israel) evaluated the mixture of probiotic products were evaluated to B infantis, Streptococcus thermophilus, The Agency for Healthcare Research determine if the bacteria species and Bifidobacteria bifidus; Dani et al24 and Quality recently issued a report listed on the label matched that (Italy) evaluated L rhamnosus GG; and on the safety of probiotics to reduce obtained by culture and polymerase Lin et al25 (Taiwan) evaluated risk and prevent or treat disease chain reaction in the laboratory. Lactobacillus acidophilus and B infantis. including 622 studies. Unfortunately, Disturbingly, only 1 of the 16 In each of these early studies, one-third of the studies reported only products containing Bifidobacterium researchers found a reduction in the nonspecific safety statements (such organisms matched the label exactly, incidence of NEC in infants who were as “well-tolerated”), and the authors and there was substantial variability randomly assigned to receive noted that adverse events were not in the composition of probiotics by lot probiotics when compared with those well documented in the majority of and pill. One of the products tested in the control group. These 3 studies studies. The conclusions of this report did not contain any of the species and those that have followed have had were as follows: “There is a lack of listed.12 wide heterogeneity of subjects and assessment and systematic reporting interventions and are also limited by of adverse events in probiotic the small number of infants with SAFETY intervention studies, and a birth weight less than 1000 g, the interventions are poorly documented. The potential infectious risk population at highest risk for NEC. The available evidence in associated with probiotic [randomized controlled trials] does The studies are hindered by supplementation may be related to not indicate an increased risk; methodologic differences among the risk of sepsis associated with the however, rare adverse events are study protocols, including different bacterial strain in the probiotic difficult to assess, and despite the strains and combinations of therapy, product that colonizes the infant or substantial number of publications, masking of trials, and having an from contamination of the product the current literature is not well a priori definition of the primary with a pathogen during the equipped to answer questions on the outcome measure. It is not clear manufacturing process. safety of probiotic interventions with whether it is appropriate to pool data Although there have been a few cases confidence.”18 Other systematic from trials by using different strains of probiotic-associated sepsis reviews have similarly reported of probiotics, leading many reported in neonates receiving inadequate reporting of adverse and investigators to urge caution in Lactobacillus rhamnosus GG,13 a meta- serious adverse events in studies interpretation of meta-analyses of analysis including more than 5000 evaluating probiotics in high-risk probiotics for the prevention of infants in randomized trials reported patients.19,20 morbidity in preterm infants.26 no systemic infection with the supplemental probiotic organism.14 The PiPS trial, conducted in the CURRENT EVIDENCE United Kingdom, was a large, Although the risk appears to be low, the potential of bacterial cross- Probiotics for the Prevention of NEC multicenter, randomized controlled colonization among infants within trial of B breve supplementation in Several recent meta-analyses have a unit is also a potential risk.15 In the 1315 very preterm infants. In evaluated the effects of probiotics to contrast to some of the earlier trials Probiotics in Very Preterm Infants prevent NEC (Bell stage 2 or 3), late- conducted in low-resource settings, in (PiPS) trial, B breve was identified as onset sepsis, and death in preterm the PiPS trial, researchers found no a cross contaminant in 37% of infants infants (typically very low birth difference in the primary outcomes of randomly assigned to the placebo weight infants). In the past 5 years, control group.16 However, it may be NEC (RR, 0.93; 95% confidence there have been numerous published interval [CI], 0.68–1.27), sepsis (RR, difficult to distinguish the change in systematic reviews.21,22 Despite great 0.97; 95% CI, 0.73–1.29), or death the infant from the change in the heterogeneity among studies, the resident flora of the NICU. (RR, 0.93; 95% CI, 0.67–1.30) before cumulative pooled risk ratio (RR) for hospital discharge.16 There have been several recent NEC (including more than 10 000 recalls of dietary supplement–grade infants) is strongly in favor of The ProPrems trial, conducted in 10 probiotics for contamination, treatment with probiotics for the perinatal centers in Australia and including with Salmonella, Rhizopus, prevention of NEC.22 New Zealand, evaluated the effect of Downloaded from www.aappublications.org/news by guest on May 27, 2021 PEDIATRICS Volume 147, number 6, June 2021 3
a probiotic combination (B infantis, advocating for caution with regard to Evaluation approach.33 Similar to the Streptococcus thermophiles, and routine use of probiotics in preterm ESPGHAN, the American Bifidobacterium lactis) in 1099 very infants. In 2010, an American Academy Gastroenterological Association made low birth weight (,1500 g) infants of Pediatrics clinical report cautioned a conditional recommendation for use with high exposure to human milk. that “the combinations of probiotics of a certain probiotic strain or strain Although no difference in the primary most convincing for NEC prevention combination for the prevention of NEC outcome of late-onset sepsis was are not available in the United States… in preterm infants but did not address found in this trial, the incidence of not all probiotics have been studied; the lack of a pharmaceutical-grade NEC (Bell stage 2 or greater) was therefore, all probiotics cannot be product for this population. reduced (2.0% vs 4.4%) in infants generally recommended.”30 In 2019, randomly assigned to receive the the Canadian Pediatric Society PROS AND CONS OF ADMINISTRATION probiotic combination (RR, 0.46; 95% reaffirmed the lack of safety and OF CURRENTLY AVAILABLE PROBIOTIC CI, 0.23–0.93). However, in efficacy data for infants with a birth PRODUCTS a prespecified subgroup analysis of weight of ,1000 g as follows: infants born at ,28 weeks’ “Probiotics may help to prevent NEC. NEC remains a devastating disease in gestational age and with a birth Administering live microorganisms to preterm infants, with high mortality and weight of ,1000 g, there was no preterm newborns should be morbidity.34 Given the number of difference in the rate of NEC.27 approached with caution. Along with publications in favor of using probiotics breastfeeding promotion, probiotics for the prevention of NEC, it is not at all Not All Probiotics Are Equal: Single can be considered for the prevention of surprising that the use of probiotics is Versus Multiple Strain NEC in preterm infants .1 kg who are increasing, even with the inherent at risk for NEC. There is currently no limitations of dietary supplement–grade Multiple-strain probiotics were data for infants weighing ,1000 g.”31 products that are currently available in associated with a significant reduction The ESPGHAN recently published the United States. A recent series of in NEC (pooled odds ratio, 0.36; 95% consensus-based guidance for the articles has eloquently outlined the pros CI, 0.24–0.53) and mortality (pooled potential use of probiotics in preterm and cons of routine usage of currently odds ratio, 0.58; 95% CI, 0.43–0.79), infants.32 With regard to the safety of available probiotic products,35,36 and whereas interventions using single- administration of probiotics to preterm other groups have also urged caution strain probiotic (usually Lactobacillus) infants, the panel stipulated that local before implementation of routine use of had only a borderline effect in laboratories should have the ability to probiotics.37 reducing NEC and no effect on mortality.28 The European Society for detect probiotic bacteremia, that only Some of the products currently Paediatric Gastroenterology, products manufactured according to available in the United States include Hepatology and Nutrition (ESPGHAN) current good manufacturing practices Culturelle (L rhamnosus GG), Similac recently published a strain-specific should be used, and that the potential Probiotic Tri-Blend (B infantis, S systematic review of the efficacy of risks and benefits are provided to thermophilus, and B lactis), and Evivo probiotics for prevention of NEC, parents of preterm infants. The panel (B infantis). Each of these highlighting important differences conditionally recommended use of L preparations are categorized as among various bacterial strains.29 rhamnosus GG (dose from 1 3 109 dietary supplements and are not CFUs to 6 3 109 CFUs) or labeled with the number of CFUs for Probiotics for the Prevention of a combination of B infantis, B lactis, and the probiotic strain(s). Culture-Proven Sepsis in Preterm S thermophilus (dose of 3.0 to 3.5 3 Infants 108 CFUs of each strain) for the reduction of stage 2 or 3 NEC but noted LONG-TERM CONSIDERATIONS In a 2014 Cochrane review that included 19 randomized or quasi- low certainty of evidence. In addition, The long-term implications of giving randomized trials of probiotic the panel recommended against the probiotics to preterm infants and how supplementation in 5338 preterm use of certain probiotic preparations on administration of microorganisms may infants, there was no evidence of the basis of safety concerns and permanently alter the microbiome is significant reduction of nosocomial uncertainty of evidence. Finally, the currently unknown. Jacobs et al38 sepsis (RR, 0.91; 95% CI, 0.80–1.03).14 panel noted the lack of evidence related found comparable rates of survival to the optimal start and length of without major neurodevelopmental treatment. Most recently, the American impairment among subjects enrolled in CURRENT PRACTICE GUIDELINES Gastroenterological Association the ProPrems trial. Although reassuring The American Academy of Pediatrics, published recommendations using the that administration of the probiotic Canadian Pediatric Society, and Grading of Recommendations preparation was not associated with ESPGHAN have all issued statements Assessment, Development and adverse neurodevelopmental Downloaded from www.aappublications.org/news by guest on May 27, 2021 4 FROM THE AMERICAN ACADEMY OF PEDIATRICS
outcomes, future studies are needed to these reasons, current evidence Ivan Hand, MD more rigorously assess the effects of does not support the routine, Ira Adams-Chapman, MD, MD Susan W. Aucott, MD probiotics on longer-term outcomes. universal administration of Karen M. Puopolo, MD probiotics to preterm infants, Jay P. Goldsmith, MD ONGOING CLINICAL TRIALS particularly those with a birth David Kaufman, MD weight of ,1000 g. Camilia Martin, MD Although many trials involving Meredith Mowitz, MD • Centers making the decision to probiotics use of a dietary administer probiotics to select supplement–grade product, a phase preterm infants should discuss the FORMER COMMITTEE MEMBER Ib study evaluating the safety and potential risks and benefits of this Brenda Poindexter, MD, MS, FAAP tolerability of 2 doses of therapy with parents and should a pharmaceutical-grade probiotic strongly consider a formalized LIAISONS (STP206; NCT01954017) in preterm informed consent process. Such infants was recently completed. In Timothy Jancelewicz, MD – American centers should develop local addition, a phase III randomized Academy of Pediatrics Section on Surgery guidelines addressing probiotic use Michael Narvey, MD – Canadian Paediatric clinical trial to evaluate the safety and and conduct surveillance to assess Society efficacy of Lactobacillus reuteri (IBP- local impacts because the Russell Miller, MD – American College of 9414; NCT03978000) to prevent NEC Obstetricians and Gynecologists introduction of probiotics has been in preterm infants is currently RADM Wanda Barfield, MD, MPH – Centers shown to alter the center’s flora ongoing. Proponents for routine for Disease Control and Prevention and potentially affect all infants Lisa Grisham, APRN, NNP-BC – National administration of probiotics for NEC cared for in the center. Association of Neonatal Nurses prevention agree that future research should compare high-quality • Clinicians must be aware of the lack probiotic products (both purity and of regulatory standards for STAFF viability of microbes) and doses.36 commercially available probiotic Jim Couto, MA preparations manufactured as dietary supplements and the SUMMARY potential for contamination with ABBREVIATIONS • In studies supporting the use of pathogenic species. probiotics to decrease the risk of CFU: colony-forming unit • Centers choosing to administer NEC and late-onset infection, CI: confidence interval probiotics should carefully researchers have used multiple ESPGHAN: European Society for document outcomes, adverse different products in diverse Paediatric Gastroenter- events, and safety. settings and in diverse preterm ology, Hepatology and target populations. The most recent Nutrition modern trials have not LEAD AUTHOR NEC: necrotizing enterocolitis demonstrated a reduction in NEC in PiPS: Probiotics in Very Preterm Brenda Poindexter, MD, MS, FAAP infants at the highest risk for this Infants morbidity. A pharmaceutical-grade RR: risk ratio probiotic product is not currently COMMITTEE ON FETUS AND NEWBORN, available in the United States. Long- 2019–2020 term safety remains unknown. For James Cummings, MD, Chairperson POTENTIAL CONFLICT OF INTEREST: The author has indicated she has no potential conflicts of interest to disclose. REFERENCES 1. Dermyshi E, Wang Y, Yan C, et al. The based review of probiotics used in very 4. Lenfestey MW, Neu J. Probiotics in “golden age” of probiotics: a systematic low birth weight preterm infants within newborns and children. Pediatr Clin review and meta-analysis of randomized the United States. J Perinatol. 2016; North Am. 2017;64(6):1271–1289 and observational studies in preterm 36(12):1106–1111 5. Pammi M, Cope J, Tarr PI, et al. Intestinal infants. Neonatology. 2017;112(1):9–23 3. Neu J. The developing intestinal dysbiosis in preterm infants preceding 2. Viswanathan S, Lau C, Akbari H, Hoyen microbiome: probiotics and prebiotics. necrotizing enterocolitis: a systematic review C, Walsh MC. Survey and evidence World Rev Nutr Diet. 2014;110:167–176 and meta-analysis. Microbiome. 2017;5(1):31 Downloaded from www.aappublications.org/news by guest on May 27, 2021 PEDIATRICS Volume 147, number 6, June 2021 5
6. Underwood MA, German JB, Lebrilla CB, 16. Costeloe K, Hardy P, Juszczak E, Wilks M, 26. Szajewska H, van Goudoever JB. To give Mills DA. Bifidobacterium longum Millar MR; Probiotics in Preterm Infants or not to give probiotics to preterm subspecies infantis: champion colonizer Study Collaborative Group. infants. Am J Clin Nutr. 2014;100(6): of the infant gut. Pediatr Res. 2015; Bifidobacterium breve BBG-001 in very 1411–1412 77(1–2):229–235 preterm infants: a randomised 27. Jacobs SE, Tobin JM, Opie GF, et al.; controlled phase 3 trial. Lancet. 2016; ProPrems Study Group. Probiotic 7. Hill C, Guarner F, Reid G, et al. Expert 387(10019):649–660 effects on late-onset sepsis in very consensus document. The International Scientific Association for Probiotics and 17. Vallabhaneni S, Walker TA, Lockhart SR, preterm infants: a randomized Prebiotics consensus statement on the et al.; Centers for Disease Control and controlled trial. Pediatrics. 2013;132(6): scope and appropriate use of the term Prevention (CDC). Notes from the field: 1055–1062 probiotic. Nat Rev Gastroenterol fatal gastrointestinal mucormycosis in 28. Chang HY, Chen JH, Chang JH, Lin HC, Hepatol. 2014;11(8):506–514 a premature infant associated with Lin CY, Peng CC. Multiple strains 8. National Institutes of Health, Office of a contaminated dietary probiotics appear to be the most Dietary Supplements. Frequently asked supplement–Connecticut, 2014. MMWR effective probiotics in the prevention of questions. Regulatory information. Morb Mortal Wkly Rep. 2015;64(6): necrotizing enterocolitis and mortality: Available at: https://ods.od.nih.gov/ 155–156 an updated meta-analysis. PLoS One. Health_Information/ODS_Frequently_ 18. Hempel S, Newberry S, Ruelaz A, et al. 2017;12(2):e0171579 Asked_Questions.aspx#Regulatory. Safety of probiotics used to reduce risk 29. van den Akker CHP, van Goudoever JB, Accessed October 13, 2020 and prevent or treat disease. Evid Rep Szajewska H, et al.; ESPGHAN Working 9. Fenster K, Freeburg B, Hollard C, Wong Technol Assess (Full Rep). 2011;(200): Group for Probiotics, Prebiotics & C, Rønhave Laursen R, Ouwehand AC. 1–645 Committee on Nutrition. Probiotics for The production and delivery of preterm infants: a strain-specific 19. Abbasi J. Are probiotics money down probiotics: a review of a practical systematic review and network meta- the toilet? Or worse? JAMA. 2019;321(7): approach. Microorganisms. 2019;7(3): analysis. J Pediatr Gastroenterol Nutr. 633–635 83 2018;67(1):103–122 20. Bafeta A, Koh M, Riveros C, Ravaud P. 30. Thomas DW, Greer FR; American 10. Drago L, Rodighiero V, Celeste T, Rovetto Harms reporting in randomized Academy of Pediatrics Committee on L, De Vecchi E. Microbiological controlled trials of interventions aimed Nutrition; American Academy of evaluation of commercial probiotic at modifying microbiota: a systematic Pediatrics Section on Gastroenterology, products available in the USA in 2009. review. Ann Intern Med. 2018;169(4): Hepatology, and Nutrition. Probiotics J Chemother. 2010;22(6):373–377 240–247 and prebiotics in pediatrics. Pediatrics. 11. Frese SA, Hutton AA, Contreras LN, et al. 2010;126(6):1217–1231 21. Sawh SC, Deshpande S, Jansen S, Persistence of supplemented Reynaert CJ, Jones PM. Prevention of 31. Marchand V. Using probiotics in the Bifidobacterium longum subsp. infantis necrotizing enterocolitis with paediatric population. Paediatr Child EVC001 in breastfed infants. mSphere. probiotics: a systematic review and Health. 2012;17(10):575–576 2017;2(6):e00501–e00517 meta-analysis. PeerJ. 2016;4:e2429 32. van den Akker CHP, van Goudoever JB, 12. Lewis ZT, Shani G, Masarweh CF, et al. 22. Patel RM, Underwood MA. Probiotics Shamir R, et al. Probiotics and Validating bifidobacterial species and and necrotizing enterocolitis. Semin preterm infants: a position paper by subspecies identity in commercial Pediatr Surg. 2018;27(1):39–46 the European Society for probiotic products. Pediatr Res. 2016; Paediatric Gastroenterology 79(3):445–452 23. Bin-Nun A, Bromiker R, Wilschanski M, Hepatology and Nutrition Committee on 13. Dani C, Coviello C C, Corsini I I, Arena F, et al. Oral probiotics prevent Nutrition and the European Society for Antonelli A, Rossolini GM. Lactobacillus necrotizing enterocolitis in very low Paediatric Gastroenterology sepsis and probiotic therapy in birth weight neonates. J Pediatr. 2005; Hepatology and Nutrition Working newborns: two new cases and 147(2):192–196 Group for Probiotics and Prebiotics. literature review. AJP Rep. 2016;6(1): 24. Dani C, Biadaioli R, Bertini G, Martelli E, J Pediatr Gastroenterol Nutr. 2020; e25–e29 Rubaltelli FF. Probiotics feeding in 70(5):664–680 14. AlFaleh K, Anabrees J. Probiotics for prevention of urinary tract infection, 33. Su GL, Ko CW, Bercik P, et al. AGA clinical prevention of necrotizing enterocolitis bacterial sepsis and necrotizing practice guidelines on the role of in preterm infants. Cochrane Database enterocolitis in preterm infants. A probiotics in the management of Syst Rev. 2014;(4):CD005496 prospective double-blind study. Biol gastrointestinal disorders. Neonate. 2002;82(2):103–108 Gastroenterology. 2020;159(2):697–705 15. Hickey L, Garland SM, Jacobs SE, O’Donnell CPF, Tabrizi SN; ProPrems 25. Lin HC, Su BH, Chen AC, et al. Oral 34. Patel RM, Kandefer S, Walsh MC, et al.; Study Group. Cross-colonization of probiotics reduce the incidence and Eunice Kennedy Shriver National infants with probiotic organisms in severity of necrotizing enterocolitis in Institute of Child Health and Human a neonatal unit. J Hosp Infect. 2014; very low birth weight infants. Development Neonatal Research 88(4):226–229 Pediatrics. 2005;115(1):1–4 Network. Causes and timing of death in Downloaded from www.aappublications.org/news by guest on May 27, 2021 6 FROM THE AMERICAN ACADEMY OF PEDIATRICS
extremely premature infants from 2000 36. Underwood MA. Arguments for routine clinical care for premature infants. through 2011. N Engl J Med. 2015; administration of probiotics for NEC Pediatrics. 2010;126(3):e741- 372(4):331–340 prevention. Curr Opin Pediatr. 2019; NaN–e745 35. Pell LG, Loutet MG, Roth DE, Sherman 31(2):188–194 38. Jacobs SE, Hickey L, Donath S, et al.; PM. Arguments against routine 37. Garland SM, Jacobs SE, Tobin JM, ProPremsStudy Groups. Probiotics, administration of probiotics for NEC Opie GF, Donath S; ProPrems study prematurity and neurodevelopment: prevention. Curr Opin Pediatr. 2019; group. A cautionary note on follow-up of a randomised trial. 31(2):195–201 instituting probiotics into routine BMJ Paediatr Open. 2017;1(1):e000176 Downloaded from www.aappublications.org/news by guest on May 27, 2021 PEDIATRICS Volume 147, number 6, June 2021 7
Use of Probiotics in Preterm Infants Brenda Poindexter and COMMITTEE ON FETUS AND NEWBORN Pediatrics originally published online May 24, 2021; Updated Information & including high resolution figures, can be found at: Services http://pediatrics.aappublications.org/content/early/2021/05/21/peds.2 021-051485 References This article cites 35 articles, 5 of which you can access for free at: http://pediatrics.aappublications.org/content/early/2021/05/21/peds.2 021-051485#BIBL Subspecialty Collections This article, along with others on similar topics, appears in the following collection(s): Committee on Fetus & Newborn http://www.aappublications.org/cgi/collection/committee_on_fetus_ _newborn Fetus/Newborn Infant http://www.aappublications.org/cgi/collection/fetus:newborn_infant_ sub Permissions & Licensing Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.aappublications.org/site/misc/Permissions.xhtml Reprints Information about ordering reprints can be found online: http://www.aappublications.org/site/misc/reprints.xhtml Downloaded from www.aappublications.org/news by guest on May 27, 2021
Use of Probiotics in Preterm Infants Brenda Poindexter and COMMITTEE ON FETUS AND NEWBORN Pediatrics originally published online May 24, 2021; The online version of this article, along with updated information and services, is located on the World Wide Web at: http://pediatrics.aappublications.org/content/early/2021/05/21/peds.2021-051485 Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 345 Park Avenue, Itasca, Illinois, 60143. Copyright © 2021 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397. Downloaded from www.aappublications.org/news by guest on May 27, 2021
You can also read